Salvage ‘DAIR’ (debridement, antibiotics and implant retention) with local injection of a selected mix of bacteriophages in an elderly patient with relapsing S. aureus prosthetic-joint infection

Tristan Ferry,1,4 * Gilles Leboucher,1 Cindy Fevre,5 Yannick Henry,1,3 Anne Conrad,1,4 Jérôme Josse,1,3, Cécile Batailler,1,3 Christian Chidiac,1,4 Mathieu Medina,5 S. Lustig,1,3 Frédéric Laurent,1,4 on behalf of the Lyon BJI Study group

1 Hospices Civils de Lyon, 2 UCBL1, 3 CRIOAcy Lyon, 4 CIRI, 5 Pherecydes Pharma

Aim

Bacteriophages have been firstly described in 1917 and remained a popular treatment in Eastern Europe for patients with osteomyelitis. As their production in such countries currently does not follow the European good manufacturing practices (GMP), bacteriophages are never used in patients with PJIs, especially due to the risk of pyrogenicity.

Method

A 80-year-old obese woman with a 5 years history of PJIs of the right hip without loosening (figure A) requiring suppressive antimicrobial therapy relapsed. Facing suspicion of relapse, the antibiotic was stopped. A purulent discharge appeared with a painful hip (figure B). S. aureus grew in culture from the swab of the pus. Pherecydes Pharma (Romainville, France) selected and manufactured (by approaching GMP standards) three bacteriophages against S. aureus from its library according to their broad and complementary spectrum, under the supervision of the French National Agency for Medicines and Health Products Safety (ANSM). The DAIR procedure (figure C) revealed pus in contact with the prosthesis. Just before joint closure, the bacteriophage mix was injected into the joint (figure D). Perioperative samples confirmed MSSA in culture but E. faecalis (susceptible to amoxicillin) and S. lugdunensis (susceptible to all antibiotics, including penicillin) were also detected. The “phagogram” i.e. a measure of the activity of the selected bacteriophages on the S. aureus strain that grew preoperatively was done retrospectively. Efficiency of each bacteriophage was tested using efficiency of plating and killing assays.

Results

The patient received daptomycin after the surgery, then oral treatment (amoxicillin and clindamycin) and finally only amoxicillin, to target E. faecalis and S. lugdunensis as suppressive antimicrobial treatment. During the follow-up, a new DAIR procedure was performed for a hematogenous C. koseri acute hip infection (S. aureus did not grow from perioperative cultures) treated with ciprofloxacin during 2 months. One year after the bacteriophages injection, still under amoxicillin, the outcome was favorable without any clinical signs of persistent infection (figure E). The phagogram revealed that only 2 of the 3 bacteriophages used were active and effective against this S. aureus strain (figure F). In addition, the bacteriophages had no activity against S. lugdunensis.

Conclusion

Local injection of a GMP-like bacteriophages mix during ‘DAIR’ was performed to treat a relapsing S. aureus chronic prosthetic-joint infection. This compassionate treatment was safe and associated with a clinical success. Scientific evaluation of the potential clinical benefit of bacteriophages in bone and joint infection is now feasible and required.
